CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Tislelizumab is now approved in nine indications in China
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Subscribe To Our Newsletter & Stay Updated
